← FDA DRUG APPROVALS

FDA ANDA · ANDA075468

CLONAZEPAM

Sponsor: RUBICON RESEARCH

APPLICATION
ANDA075468
TYPE
ANDA
ORIGINAL APPROVAL
2000-10-06
LATEST ACTION
2026-06-12
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CLONAZEPAMPrescription
CLONAZEPAM 0.5MG · TABLET · ORAL
CLONAZEPAMPrescription
CLONAZEPAM 0.25MG · TABLET · ORAL
CLONAZEPAMPrescription
CLONAZEPAM 1MG · TABLET · ORAL
CLONAZEPAMPrescription
CLONAZEPAM 2MG · TABLET · ORAL

Approval history

2026-06-12Manufacturing (CMC) · Supplement 31 · unknownAP
2016-07-18Labeling · Supplement 19 · standardAP
2015-08-10Labeling · Supplement 18 · standardAP
2013-05-31Labeling · Supplement 17 · standardAP
2010-07-06Labeling · Supplement 16AP
2003-08-04Labeling · Supplement 4AP
2002-01-08Labeling · Supplement 3AP
2002-01-08Manufacturing (CMC) · Supplement 1AP
2002-01-08Manufacturing (CMC) · Supplement 2AP
2000-10-06OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →